First Patient Dosed in Phase 1 Trial of MM-310 as Treatment for Ovarian, Other Cancers

First Patient Dosed in Phase 1 Trial of MM-310 as Treatment for Ovarian, Other Cancers
The first patient has been dosed in a Phase 1 trial of MM-310 as a treatment for solid tumors, according to its developer, Merrimack Pharmaceuticals. MM-310 is an EphA2 receptor-targeted vesicle — or fluid-containing sac — that carries a taxane to tumor cells. A taxane is a therapy that stops cell growth by preventing cells

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *